Proctitis accounts for a significant proportion of cases of ulcerative colitis (UC), and some patients subsequently develop more extensive disease. However, most patients continue to have limited inflammation, although the changes in the distal colon and rectum can occasionally be severe, and symptoms of increased frequency, rectal bleeding and urgency can be as disabling as they are for patients with more extensive colitis. Furthermore, although symptoms are typically well controlled with standard medications, medically refractory proctitis poses particular problems. Patients generally are not systemically unwell, and there is no added fear of cancer. Therefore, the prospect of colectomy for such limited disease is resisted by patients, physicians and surgeons alike. Unusual therapies, often delivered locally by enema or suppository, have been tested in small case series without definitive outcomes. The pathogenesis of such limited, yet intractable inflammation remains unclear, and the differential diagnosis should be carefully reviewed to ensure that local disease, whether it is infectious, vascular, or a result of injury or degeneration, is not overlooked. Ileo-anal pouch formation is the surgery of choice for about 20% of patients with UC who undergo colectomy. In the majority of cases, this surgery results in an acceptable quality of life and freedom from a stoma. However, in a sizeable minority of cases, pouch dysfunction can cause intractable problems. The causes of pouch dysfunction are varied and must all be considered carefully, particularly in refractory cases. Pouchitis is a common issue and is usually transient and easily treated. However, refractory and chronic pouchitis can be challenging. Ischaemia, injury, infection and Crohn's disease can all cause refractory pouch dysfunction. In a minority of cases, there appears to be no apparent organic pathology, and the presumptive diagnosis is that of a functional pouch disorder. Although it is much rarer, neoplastic changes in the pouch must also be considered, and the risk managed appropriately. The management of both intractable proctitis and the problematic pouch is made more challenging by the wide differential diagnosis that must be considered and by the paucity of high-quality clinical trials to support any one therapy. Key strategies to overcoming these limitations include methodical and systematic investigation and review, and a willingness to tailor therapy to the individual patient. Clinical trials of new treatments should be supported, and data from the experience with small cohorts of patients should be meticulously collected, critically analysed and widely disseminated.

Keywords:
Ileal pouch-anal anastomosis, Pouch, Pouchitis, Proctitis
1.
Jess T, et al: Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007;13:481-489.
2.
Eaden JA, et al: Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 2002;51(suppl 5):V10-V12.
3.
Meucci G, et al: The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol 2000;95:469-473.
4.
Solberg IC, et al: Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-440.
5.
Marshall JK, et al: Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010:CD004115.
6.
Dignass A, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
7.
Lamet M: A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg twice daily in patients with active mild-to-moderate ulcerative proctitis. Dig Dis Sci 2011;56:513-522.
8.
Andus T, et al: Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis 2010;16:1947-1956.
9.
Cohen RD, et al: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol 2000;95:1263-1276.
10.
Safdi M, et al: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997;92:1867-1871.
11.
Gionchetti P, et al: Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998;41:93-97.
12.
Mantzaris GJ, et al: Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 1994;37:58-62.
13.
van Bodegraven AA, et al: Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 1996;10:327-332.
14.
Mulder CJ, et al: Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996;8:549-553.
15.
Pica R, et al: Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. Inflamm Bowel Dis 2004;10:731-736.
16.
Richter JM, et al: Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. Aliment Pharmacol Ther 2012;36:248-256.
17.
Jarnerot G: Clinical tolerance of olsalazine. Scand J Gastroenterol Suppl 1988;148:21-23.
18.
Lamb CA, et al: Sexually transmitted infections manifesting as proctitis. Frontline Gastroenterol 2013;4:32-40.
19.
Tas A, et al: Psoriatic colitis mimicking ulcerative proctitis in an elderly patient. Chin Med J (Engl) 2012;125:2080.
20.
Tas A, et al: Hydrogen peroxide exposure mimicking ulcerative proctitis. Dig Liver Dis 2011;43:331-332.
21.
Langevin S, et al: Idiopathic ulcerative proctitis may be the initial manifestation of Crohn's disease. J Clin Gastroenterol 1992;15:199-204.
22.
Jarnerot G, Rolny P, Sandberg-Gertzen H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-1013.
23.
Campbell S, Travis S, Jewell D: Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84.
24.
Rutgeerts P, et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
25.
Ferrante M, et al: Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2:219-225.
26.
Bouguen G, et al: Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther 2010;31:1178-1185.
27.
Molnar T, et al: Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. Am J Gastroenterol 2009;104:1857-1858.
28.
Vegter S, et al: Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2013;38:284-293.
29.
Feagan BG, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
30.
Sandborn WJ, et al: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96.e1-109.e1.
31.
Sandborn WJ, et al: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95.
32.
Vermeire S, et al: Differentiation between etrolizumab (rhuMAb beta7) and placebo in the Eucalyptus phase II randomized double-blind placebo-controlled induction study to evaluate efficacy and safety in patients with refractory moderate-to severely active ulcerative colitis. Gastroenterology 2013;144 (suppl 1):S-36.
33.
Lawrance IC, Copeland TS: Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-1220.
34.
van Dieren JM, et al: Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009;15:193-198.
35.
Makiyama K, Takeshima F, Hamamoto T: Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005;50:2323-2329.
36.
Sinha A, et al: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349:350-357.
37.
Arlander E, et al: Ropivacaine gel in active distal ulcerative colitis and proctitis - a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 1996;10:73-81.
38.
Bjorck S, Ahlman H, Dahlstrom A: Lignocaine and ulcerative proctitis. Lancet 1988;1:1330.
39.
Srivastava ED, et al: Tripotassium dicitrato bismuthate enemas in the treatment of ulcerative proctitis. Aliment Pharmacol Ther 1990;4:577-581.
40.
Forbes A, et al: Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989;3:553-556.
41.
Fukunaga K, et al: Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. J Gastroenterol Hepatol 2012;27:1808-1815.
42.
Zhang F, et al: Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. J Altern Complement Med 2013;19:838-842.
43.
Singla V, et al: Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis 2013, Epub ahead of print.
44.
Bolin TD, et al: Appendicectomy as a therapy for ulcerative proctitis. Am J Gastroenterol 2009;104:2476-2482.
45.
Dumortier J, Scoazec JY, Ponchon T: Treatment of refractory ulcerative proctitis with argon plasma coagulation: case report. Gastrointest Endosc 2004;60:317-319.
46.
Samuel S, et al: Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013;19:1858-1866.
47.
Sandborn WJ, et al: Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-1260; quiz 1520.
48.
Gustavsson A, et al: Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010;32:984-989.
49.
Ehteshami-Afshar S, et al: A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci 2011;7:1000-1012.
50.
Parks AG, Nicholls RJ: Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 1978;2:85-88.
51.
Van Assche G, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3: special situations. J Crohns Colitis 2013;7:1-33.
52.
Fazio VW, et al: Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120-127.
53.
Shen B, et al: Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002;97:972-977.
54.
Meagher AP, et al: J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998;85:800-803.
55.
Penna C, et al: Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993;80:765-767.
56.
Kiehne K, et al: Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 2006;12:1056-1062.
57.
Shen B: Bacteriology in the etiopathogenesis of pouchitis. Dig Dis 2012;30:351-357.
58.
Joelsson M, Benoni C, Oresland T: Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis? Scand J Gastroenterol 2006;41:929-933.
59.
Aisenberg J, et al: Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004;99:432-441.
60.
Carter MJ, et al: The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001;121:805-811.
61.
Meier CB, et al: Innate immune receptor genetic polymorphisms in pouchitis: is CARD15 a susceptibility factor? Inflamm Bowel Dis 2005;11:965-971.
62.
Hashavia E, et al: Risk factors for chronic pouchitis after ileal pouch-anal anastomosis: a prospective cohort study. Colorectal Dis 2012;14:1365-1371.
63.
Fleshner P, et al: A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007;5:952-958; quiz 887.
64.
Okita Y, et al: Predictive factors for development of chronic pouchitis after ileal pouch-anal anastomosis in ulcerative colitis. Digestion 2013;88:101-109.
65.
Penna C, et al: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-239.
66.
Singh S, et al: Meta-analysis: serological markers and the risk of acute and chronic pouchitis. Aliment Pharmacol Ther 2013;37:867-875.
67.
Poritz LS, et al: Chronic use of PPI and H2 antagonists decreases the risk of pouchitis after IPAA for ulcerative colitis. J Gastrointest Surg 2013;17:1027-1031.
68.
Pastrana RJ, et al: Iron-deficiency anemia as presentation of pouchitis. J Clin Gastroenterol 2007;41:41-44.
69.
Shepherd NA, et al: Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987;40:601-607.
70.
Moskowitz RL, Shepherd NA, Nicholls RJ: An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986;1:167-174.
71.
Moonka D, et al: Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol 1998;93:264-266.
72.
Araujo Miguez A, et al: Pouchitis associated with cytomegalovirus infection: a case study. Inflamm Bowel Dis 2013;19:E65-E66.
73.
Tribonias G, et al: Detection of CMV in pouch mucosa in a patient with acute pouchitis: the real enemy or an innocent bystander? J Crohns Colitis 2012;6:728-729.
74.
Johnson MW, et al: Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol 2008;20:174-179.
75.
Sandborn WJ, et al: Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994;69:409-415.
76.
Lohmuller JL, et al: Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990;211:622-627; discussion 627-629.
77.
Shen B: Acute and chronic pouchitis - pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2012;9:323-333.
78.
Shen B, et al: A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-305.
79.
Holubar SD, et al: Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2010:CD001176.
80.
Isaacs KL, et al: Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007;13:1250-1255.
81.
Pepin J, et al: Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-1260.
82.
Muzi F, et al: Fluoroquinolones-induced tendinitis and tendon rupture in kidney transplant recipients: 2 cases and a review of the literature. Transplant Proc 2007;39:1673-1675.
83.
Duffy LF, et al: Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985;88:681-684.
84.
McLaughlin SD, et al: Fecal coliform testing to identify effective antibiotic therapies for patients with antibiotic-resistant pouchitis. Clin Gastroenterol Hepatol 2009;7:545-548.
85.
Steffen R: Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea. J Travel Med 2001;8(suppl 2):S34-S39.
86.
Shen B, et al: Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol 2008;8:26.
87.
Ham M, Moss A: Oral ertapenem for refractory pouchitis. J Crohns Colitis 2013;7:e501-e502.
88.
Shen B, et al: Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007;50:498-508.
89.
Abdelrazeq AS, et al: Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005;7:182-186.
90.
Mimura T, et al: Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-917.
91.
McLaughlin SD, et al: An open study of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis: efficacy, complications and outcome. Colorectal Dis 2011;13:438-444.
92.
Clement A, et al: Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006;61:895-902.
93.
Ramsey BW, et al: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
94.
Mimura T, et al: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108-114.
95.
Shen B, et al: Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther 2005;22:721-728.
96.
Shen B, et al: Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2011;17:994-1002.
97.
Sambuelli A, et al: Budesonide enema in pouchitis - a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002;16:27-34.
98.
Cabriada Nuno JL, et al: Oral budesonide in the treatment of chronic refractory pouchitis (in Spanish). Gastroenterol Hepatol 2008;31:485-489.
99.
Gionchetti P, et al: Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-1236.
100.
Barreiro-de Acosta M, et al: Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012;18:812-817.
101.
Viazis N, et al: Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis. J Crohns Colitis 2013;7:e457-e460.
102.
Barreiro-de Acosta M, et al: Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012;24:756-758.
103.
Uchino M, et al: Topical tacrolimus therapy for antibiotic-refractory pouchitis. Dis Colon Rectum 2013;56:1166-1173.
104.
Miner P, et al: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004;19:281-286.
105.
Wischmeyer P, Pemberton JH, Phillips SF: Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc 1993;68:978-981.
106.
Gionchetti P, et al: Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Aliment Pharmacol Ther 1997;11:673-678.
107.
Tremaine WJ, et al: Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 1997;11:1041-1046.
108.
Belluzzi A, et al: Pilot study: the use of sulfasalazine for the treatment of acute pouchitis. Aliment Pharmacol Ther 2010;31:228-232.
109.
McLaughlin SD, et al: Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis. J Crohns Colitis 2013;7:460-466.
110.
Daniels, Beynon, Carr: The use of cyclosporin retention enemas for pouchitis. Colorectal Dis 1999;1:49.
111.
Tekkis PP, et al: Long-term results of abdominal salvage surgery following restorative proctocolectomy. Br J Surg 2006;93:231-237.
112.
Mathis KL, et al: Outcomes in patients with ulcerative colitis undergoing partial or complete reconstructive surgery for failing ileal pouch-anal anastomosis. Ann Surg 2009;249:409-413.
113.
Zmora O, et al: Reoperative abdominal and perineal surgery in ileoanal pouch patients. Dis Colon Rectum 2001;44:1310-1314.
114.
Thompson-Fawcett MW, Mortensen NJ, Warren BF: ‘Cuffitis' and inflammatory changes in the columnar cuff, anal transitional zone, and ileal reservoir after stapled pouch-anal anastomosis. Dis Colon Rectum 1999;42:348-355.
115.
Shen B, et al: Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004;99:1527-1531.
116.
Wu B, et al: Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch-anal anastomoses. Inflamm Bowel Dis 2013;19:404-410.
117.
Shen B: Crohn's disease of the ileal pouch: reality, diagnosis, and management. Inflamm Bowel Dis 2009;15:284-294.
118.
Colombel JF, et al: Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003;98:2239-2244.
119.
Ricart E, et al: Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999;117:429-432.
120.
Li Y, et al: Adalimumab therapy in Crohn's disease of the ileal pouch. Inflamm Bowel Dis 2012;18:2232-2239.
121.
Shen B, et al: Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment Pharmacol Ther 2009;29:519-526.
122.
Matzke GM, et al: Mid pouch strictureplasty for Crohn's disease after ileal pouch-anal anastomosis: an alternative to pouch excision. Dis Colon Rectum 2004;47:782-786.
123.
Veress B, et al: Long-term histomorphological surveillance of the pelvic ileal pouch: dysplasia develops in a subgroup of patients. Gastroenterology 1995;109:1090-1097.
124.
Um JW, M'Koma AE: Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Tech Coloproctol 2011;15:7-16.
125.
Banasiewicz T, et al: Pouchitis may increase the risk of dysplasia after restorative proctocolectomy in patients with ulcerative colitis. Colorectal Dis 2012;14:92-97.
126.
Stahlberg D, et al: Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003;46:770-778.
127.
Kariv R, et al: Preoperative colorectal neoplasia increases risk for pouch neoplasia in patients with restorative proctocolectomy. Gastroenterology 2010;139:806-812, 812.e1-e2.
128.
Thompson-Fawcett MW, et al: Risk of dysplasia in long-term ileal pouches and pouches with chronic pouchitis. Gastroenterology 2001;121:275-281.
129.
Liu ZX, et al: Diagnosis and management of dysplasia and cancer of the ileal pouch in patients with underlying inflammatory bowel disease. Cancer 2011;117:3081-3092.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.